Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Moderna Marches First Coronavirus Vaccine To US Test

Enters Clinic In Just 42 days

Executive Summary

The first vaccine for the new coronavirus has entered the clinic, with US firm Moderna leading the race.

You may also be interested in...



Sanofi Joins mRNA COVID-19 Club With Translate Tie-Up

The French drugmaker has joined the likes of Moderna, BioNTech and CureVac in advancing an mRNA vaccine against the virus that causes COVID-19 that could take the fraction of the time to develop compared with the old egg- and cell-based technology.

CureVac Denies Takeover Reports As It Slates Phase I Coronavirus Vaccine Study For Early Summer

The German biotech firm has denied receiving any offer from the Trump administration in a wide-ranging conference call that also addressed recent changes at the top, its clinical timeline for a coronavirus vaccine and new funds from the European Commission to boost production.

Pfizer, Fosun Partner BioNTech On mRNA COVID-19 Vaccine

BioNTech extends Pfizer partnership to cover COVID-19 vaccine development and distribution while Fosun Pharma takes Chinese rights.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC141719

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel